Discover
ENTX
Entera Bio Ltd.
1.69
1 x 1.77
1 x 1.67
bid
ask
-
0.08
4.52%
1 @ 04:00 PM
1.75 +0.06 (3.55%)
| Ytd | -12.89% | |
| 1y | -9.14% |
1.69
day range
1.90
0.91
52 week range
3.22
| Open | 1.75 | Prev Close | 1.77 | Low | 1.69 | High | 1.90 | Mkt Cap | 83.30M |
| Vol | 401.71K | Avg Vol | 1.04M | EPS | -0.26 | P/E | N/A | Forward P/E | -3.64 |
| Beta | 1.59 | Short Ratio | 0.54 | Inst. Own | 18.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.28 | 200-d Avg | 1.68 | 1yr Est | 10.00 |
ENTX News
benzinga.com
Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Compa
Entera Bio (NASDAQ:ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provid
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul
benzinga.com
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protoco
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the developm
benzinga.com
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward C
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust
benzinga.com
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Repo
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the developme